Algert Global LLC Increases Stock Position in Glaukos Co. (NYSE:GKOS)

Algert Global LLC boosted its position in Glaukos Co. (NYSE:GKOS - Free Report) by 41.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 18,821 shares of the medical instruments supplier's stock after acquiring an additional 5,561 shares during the period. Algert Global LLC's holdings in Glaukos were worth $2,822,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Barclays PLC increased its stake in shares of Glaukos by 394.4% in the third quarter. Barclays PLC now owns 89,699 shares of the medical instruments supplier's stock worth $11,686,000 after purchasing an additional 71,556 shares in the last quarter. Franklin Resources Inc. boosted its holdings in Glaukos by 80.1% in the 3rd quarter. Franklin Resources Inc. now owns 15,621 shares of the medical instruments supplier's stock worth $2,031,000 after buying an additional 6,948 shares during the period. Harbor Capital Advisors Inc. bought a new position in Glaukos in the 4th quarter worth approximately $3,679,000. Oak Ridge Investments LLC purchased a new position in Glaukos in the 4th quarter valued at approximately $1,672,000. Finally, LVW Advisors LLC raised its holdings in Glaukos by 22.2% during the 4th quarter. LVW Advisors LLC now owns 2,273 shares of the medical instruments supplier's stock valued at $341,000 after acquiring an additional 413 shares during the period. 99.04% of the stock is currently owned by institutional investors.

Glaukos Price Performance

Shares of GKOS stock traded up $0.12 during trading on Tuesday, hitting $94.76. The company had a trading volume of 138,194 shares, compared to its average volume of 680,229. The stock's 50-day moving average is $94.52 and its two-hundred day moving average is $127.06. The stock has a market capitalization of $5.41 billion, a price-to-earnings ratio of -33.02 and a beta of 0.83. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 52 week low of $77.10 and a 52 week high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. The firm had revenue of $106.66 million for the quarter, compared to analyst estimates of $102.78 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business's revenue for the quarter was up 24.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.70) EPS. As a group, analysts predict that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on GKOS. Truist Financial reaffirmed a "buy" rating and issued a $135.00 price target (down from $140.00) on shares of Glaukos in a report on Thursday, May 1st. Stephens cut their target price on Glaukos from $140.00 to $115.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Mizuho reduced their target price on Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a report on Wednesday, April 16th. Needham & Company LLC lowered their price target on shares of Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Finally, Morgan Stanley cut their price objective on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Glaukos presently has a consensus rating of "Moderate Buy" and an average target price of $134.67.

Insider Activity at Glaukos

In other news, insider Tomas Navratil sold 3,416 shares of the company's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares in the company, valued at approximately $10,658,380.18. This represents a 4.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Alex R. Thurman sold 1,520 shares of the firm's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the transaction, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. This represents a 2.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.80% of the stock is owned by insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.